Clearpoint Neuro Stock News

Even though elective procedures are returning to the pre-pandemic level, the rise of the Omicron variant resurgence may continue to impact the case volume in the upcoming quarters. ClearPoint Neuro is

ClearPoint Neuro Inc (CLPT) shares closed today at 2.0% above its 52 week low of $10.10, giving the company a market cap of $243M. The stock is currently down 8.1% year-to-date, down 34.1% over the past 12 months, and up 796.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 5.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 75.7% The company's stock price performance over the past 12 months lags the peer average by 5.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ClearPoint Neuro Inc (CLPT) shares closed today at 1.9% above its 52 week low of $10.12, giving the company a market cap of $249M. The stock is currently down 6.0% year-to-date, down 31.2% over the past 12 months, and up 817.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 13.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 126.6% The company's stock price performance over the past 12 months lags the peer average by 13.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the b

Related Stocks: ABOS , CLPT , RBLX , SSNC ,

ClearPoint Neuro, Inc. (CLPT) CEO Joseph Burnett on Q3 2021 Results - Earnings Call Transcript

ClearPoint provides a complete navigation system that enables neurosurgeons to perform minimally invasive procedures under a real-time guidance. Once the full portfolio of products is released, the co

ClearPoint Neuro Inc (NASDAQ: CLPT) reported Q2 revenue of $3.4 million, a 38% Y/Y increase, below the consensus estimate of $3.68 million. Functional neurosurgery navigation revenue increased 74% t

ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2021 Results - Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -21.43% and -1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of ClearPoint Neuro (NASDAQ:CLPT) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 54.55% year over year to ($0.17), which

ClearPoint Neuro is both a medical device and a biologics & drug delivery company. Both opportunities leverage a common navigation system with superior advantages over existing solutions. New product

ClearPoint Neuro, Inc. (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri

If you are a growth investor, there is nothing more tantalizing than finding a company that could potentially grow by ten times or more in the future.

SOLANA BEACH, Calif. and SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation an